864244-98-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Methyl-4-Nitrophenoxy)Pyridin-2-Amine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to inhibit specific biological processes, making it a promising candidate for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(2-Methyl-4-Nitrophenoxy)Pyridin-2-Amine is utilized as a precursor in the production of pesticides. Its ability to interfere with biological pathways makes it a potential component in creating effective pest control solutions.
Used in Materials Science:
4-(2-Methyl-4-Nitrophenoxy)Pyridin-2-Amine is used as a component in the development of organic semiconductors and dyes. Its chemical properties contribute to the creation of innovative materials with potential applications in various fields.
It is crucial to handle 4-(2-Methyl-4-Nitrophenoxy)Pyridin-2-Amine with care and follow proper safety protocols due to its potential hazards.

Upstream product

• 937263-40-6 tert-butyl 4-(2-methyl-4-nitrophenoxy)pyridin-2-ylcarbamate 
• 19798-80-2 2-Amino-4-chloropyridine 
• 99586-65-9 4-chloropicolinamide 
• 98-98-6 2-Picolinic acid 
• 202216-99-7 4-chloro-2-pyridinamine hydrochloride 
• 455-88-9 5-nitro-2-fluorotoluene 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 33631-05-9 2-amino-4-hydroxypyridine 
• 99-53-6 2-methyl-4-nitrophenol 
• 65370-42-5 4-chloro-2-nitropyridine 

Downstream Products

• 937263-41-7 7-(2-methyl-4-nitrophenoxy)imidazo [1,2-a]pyridine 
• 937263-44-0 7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a] pyridine 
• 937263-71-3 4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylaniline 
• 937263-43-9 tucatinib 
• 1229607-60-6 2-methoxy-N-(4-(2-methyl-4-nitrophenoxy)pyridin-2-yl)acetamide 
• 864245-03-4 1-(3-diethylaminopropyl)-3-[4-(2-methyl-4-nitrophenoxy)pyridin-2-yl]urea 

Relevant academic research and scientific papers

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF

The present invention relates to a group of pyrrolo[2, 1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

Synthesis method of Tucatinib and intermediate product thereof

The invention discloses a synthesis method of Tucatinib, and the method comprises the following step: carrying out substitution reaction on halate of a compound shown in a formula VI or free alkali thereof serving as a raw material and a compound shown in a formula VII under an alkaline condition to obtain a compound shown in a formula VIII. The raw materials used in the whole synthesis route areeasy to obtain, expensive catalysts are not needed, and the method is suitable for large-scale production and beneficial to industrial production of the Tucatinib.

New Synthetic Route to Tucatinib

A new and improved synthetic route to tucatinib is described that involves three key intermediates. The first of these, 4-([1,2,4]triazolo[1,5- a ]pyridin-7-yloxy)-3-methylaniline, was prepared on a 100 g scale in 33percent yield over five steps and 99percent purity. Next, N 4 -(4-([1,2,4]triazolo[1,5- a ]pyridin-7-yloxy)-3-methylphenyl)quinazoline-4,6-diamine was isolated in 67percent yield over three steps and >99percent purity. Then, 4,4-dimethyl-2-(methylthio)-4,5-dihydrooxazole trifluoromethanesulfonate was prepared under mild conditions in 67percent yield over two steps. Finally, tucatinib was obtained in 17percent yield over nine steps and in >99percent purity (HPLC). Purification methods used to isolate the product and the intermediates involved in the route are also reported.

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

Irbinitinib intermediates for preparation of (by machine translation)

The invention belongs to the organic synthesis and bulk drug preparation technology field, in particular to the treatment of breast cancer drug Irbinitinib preparation method and intermediate, comprising the steps of: 2 - methyl - 4 - nitro-phenol (formul

Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives

This invention provides compounds of Formula (I), wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen or the like.]